Burning mouth syndrome in Parkinson’s disease: dopamine as cure or cause? by Coon, Elizabeth A. & Laughlin, Ruple S.
BRIEF REPORT
Burning mouth syndrome in Parkinson’s disease:
dopamine as cure or cause?
Elizabeth A. Coon • Ruple S. Laughlin
Received: 12 January 2012/Accepted: 28 January 2012/Published online: 10 February 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Burning mouth syndrome has been reported as
being more common in Parkinson’s disease patients than
the general population. While the pathophysiology is
unclear, decreased dopamine levels and dopamine
dysregulation are hypothesized to play a role. We report a
patient with Parkinson’s disease who developed burning
mouth syndrome with carbidopa/levodopa. Our patient had
resolution of burning mouth symptoms when carbidopa/
levodopa was replaced with a dopamine agonist. Based on
our patient’s clinical course, in conjunction with earlier
studies assessing the relationship between burning mouth
syndrome and Parkinson’s disease, we discuss a potential
role for dopamine in burning mouth syndrome in Parkinson’s
disease.
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Introduction
Burning mouth syndrome is characterized by a painful,
intraoral burning sensation that lacks physical or laboratory
ﬁndings. In the general population, postmenopausal women
and the elderly are most often affected, with a prevalence
ranging from 3.7 to 18% [1]. Burning mouth syndrome
may be more common in Parkinson’s disease with one
study reporting a 24% prevalence in Parkinson’s disease
patients [2]. All of these patients developed burning mouth
symptoms after the diagnosis of Parkinson’s disease and
96% were taking levodopa. However, this study was from a
selected population in Northern Ireland and limited by size
with only 115 valid respondents [2].
Diminished endogenous dopamine and dysregulation of
dopaminergic receptors in the nigrostriatal pathway has
been implicated as one pathophysiologic mechanism for
primary burning mouth syndrome [3, 4]. We report a
Parkinson’s disease patient who developed burning mouth
syndrome after starting carbidopa/levodopa and had
improvement of her symptoms after discontinuation of
carbidopa/levodopa and resolution upon initiation of a
dopamine agonist. Based on our case and ﬁndings from
earlier studies, we discuss potential mechanisms of burning
mouth syndrome in Parkinson’s disease.
Case presentation
A 65-year-old right-handed woman was diagnosed with aki-
netic-rigid Parkinson’s disease after a 4-year history of pro-
gressive right arm stiffness associated with musculoskeletal
pain. She had been maintained only on a low dose of pram-
ipexole (0.25 mg three times daily) due to feelings of anxiety
at higher doses. On initial neurologic examination, she dem-
onstrated hypomimia and hypokinetic dysarthria. She had
cogwheel rigidity and slowed rapid alternating movements
with the right-upper extremity and a bradykinetic gait with
absent right arm swing. Based on the patient’s reluctance to
escalate the dose of pramipexole, it was tapered off and
replaced with carbidopa/levodopa 25/100 mg tablets titrated
toadoseof1.5tabletsthreetimesperday.Onthisregimenshe
experienced marked improvement in her Parkinson’s disease
symptoms.
Six weeks after starting carbidopa/levodopa, the patient
beganexperiencingburning,‘‘peeling’’sensationsinvolving
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The pain typically worsened throughout the day and became
severe enough to prompt an urgent care visit where she was
prescribed a course of oral nystatin with no relief. Oral and
dental examinations were normal and she experimented with
different toothbrushes and toothpastes, ice cubes, gum and
hard candies with avoidance of spices, mint and citrus prod-
uctstonoavail.Hermouthsymptomsintensiﬁedaftershewas
prescribed additional carbidopa for nausea associated with
levodopa doses, leading to discontinuation of the additional
carbidopa. She was evaluated by otolaryngology and derma-
tology and had a negative laboratory evaluation including
complete blood count, vitamin B1, B2, B6 and B12, magne-
sium, zinc, folate, ferritin, thyroid stimulating hormone and
anti-nuclearantibody.Shewasdiagnosedwithburningmouth
syndromeandprescribedclonazepam0.5 mgtabstodissolve
inthemouthwhichofferednorelief.Duetothecorrelationof
symptom onset with initiation of carbidopa/levodopa, this
medication was discontinued. Over the next 2 weeks her
symptoms improved with only residual dysesthesia affecting
the tip of her tongue. Unfortunately, her Parkinson’s disease
symptoms concomitantly worsened with return of her right
upper limb rigidity and pain and new stiffness involving her
left upper limb. Pramipexole was re-initiated and titrated to a
dose of 1.5 mg orally three times daily which led to the
improvement of her Parkinson’s disease symptoms similar to
that achieved with carbidopa/levodopa and she had complete
resolution of her burning mouth symptoms.
Discussion
Carbidopa/levodopa was considered causative for burning
mouth syndrome in our patient as symptom onset and
severity correlated directly with its administration and
titration. The response to dopaminergic therapy in our
patient is unusual as central pain syndromes in Parkinson’s
disease, such as oral and genital pain, are more likely to
respond to dopaminergic therapy than other types of pain
[5, 6]. Central and peripheral pain in Parkinson’s disease
are recognized as distinct processes; the origin of central
pain is not clearly understood while peripheral pain appears
to be from abnormal nociceptive processing [6]. Of inter-
est, our patient also exhibited musculoskeletal limb pain
associated with Parkinson’s disease (on the affected side)
which responded to levodopa therapy. This is consistent
with previous reports in Parkinson’s disease where pain
was predominantly a factor in the ‘off’ or dopamine deﬁ-
cient state [6]. Our case suggests that the mechanisms
underlying burning mouth syndrome in Parkinson’s disease
may differ from other types of pain in Parkinson’s disease.
Burning mouth syndrome has also been analogized to
restless leg syndrome, a syndrome related to dopaminergic
dysfunction [7]. In restless leg syndrome, high doses of
dopamine may paradoxically lead to worsening and aug-
mentation of symptoms after initial beneﬁt [8]. One hypoth-
esis is that overstimulation of pro-nociceptive D1 receptors
compared to anti-nociceptive D2 receptors leads to pain.
StudiessupportingthishaveshownreducedD2receptors,but
not D1 receptors in hyperdopaminergic states [8–10]. In ani-
mal models, sensitivity of dopaminergic receptors has been
augmented by levodopa, with a nociceptive effect that was
depressed by blockage of D1 receptors [10].
Studies in primary burning mouth syndrome have shown
dysfunction of the nigrostriatal dopaminergic pathway [1, 3,
4]. Positron emission tomography studies of burning mouth
syndrome patients without Parkinson’s disease indicate low
levels of endogenous dopamine in nigrostriatal neurons
compared to controls [3], and demonstrate alterations in the
binding of D1 and D2 receptors in the putamen [4]. This is
intriguing as increasing central dopamine levels with
additional carbidopa led to dramatic worsening in our
patient’s burning mouth symptoms. Treatment was
achieved by withdrawing excess dopamine and substituting
pramipexole, a D2 and D3 dopamine receptor agonist.
While caution is advised in interpreting an individual
case, burning mouth syndrome in our patient with Parkin-
son’s disease could be explained by dysregulation of
dopamine receptors in an endogenous hypodopaminergic
state. In the presence of excess dopamine, exaggerated D1
compared to D2 receptor activity may have caused burning
mouth symptoms. Pramipexole has been reported as a
therapy in primary burning mouth syndrome, and success in
our patient supports its use as a treatment choice for burning
mouth syndrome in Parkinson’s disease patients [7].
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